Navigation Links
New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline
Date:9/16/2013

e look forward to completing the acquisition in the coming months, which we believe will establish Mylan as a global injectables leader, with a significantly expanded and strengthened injectables portfolio, pipeline, platform and capabilities." The Company expects the transaction to close in Q4 2013, subject to remaining regulatory approvals and certain closing conditions. The Full Research Report on Mylan, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-11/MYL]

--

AstraZeneca PLC Research Report

On September 11, 2013, AstraZeneca PLC (AstraZeneca) announced that it has entered into a worldwide licensing agreement with Merck Co. Inc. (Merck) for the latter's oral small molecule inhibitor of WEE1 kinase (MK-1775). The Company informed that MK-1775 is undergoing evaluation in Phase IIa clinical studies in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer. Under the terms of agreement, AstraZeneca will pay $50 million upfront fee and will be responsible for all future clinical development, manufacturing and marketing, while Merck will be eligible to receive future payments tied to development and regulatory milestones plus sales-related payments and tiered royalties. "MK-1775 is a strong addition to AstraZeneca's growing oncology pipeline, which already includes a number of inhibitors of the DNA damage response," said Susan Galbraith, Head of AstraZeneca's Oncology Innovative Medicines Unit. "The compound has demonstrated encouraging clinical efficacy data and we intend to study it in a range of cancer types where there is a high unmet medical need." The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is avail
'/>"/>

SOURCE Investors' Reports
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Manipulating way bacteria talk could have practical applications, Texas A&M profs say
2. Research and Markets: Nanobiotechnology Applications, Markets and Companies - 2013 Report
3. Carbon Nanotubes (CNT) for Electronics & Electrics 2013-2023: Forecasts, Applications, Technologies
4. California Biomedical Companies Report Higher Product Approvals, Fewer Delays
5. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
6. SpermCheck® Fertility, the Only FDA Approved At-Home Screening Test for Men to Determine Normal or Low Sperm Count, Now Available to Couples Planning or Struggling to Conceive
7. K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court
8. K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court
9. Pinnaclife Animal Health Features Seal N Heal Wound Shield in New Veterinary Dermatologist Tested and Approved Product Line!
10. Recently FDA-Approved Full Neck Treatment for Sagging Skin Now Available at Maryland Laser Skin and Vein Institute
11. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... NEW YORK , Oct. 20, 2014 /PRNewswire/ ... of their experimental ZMapp™ antibody therapeutic to fight ... of how difficult and time-consuming the production of ... healthcare market research publisher said that while some ... cycle of this compound, those with industry knowledge ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... 2014 , A major pan-European ... the delivery of care has revealed changing trends in ... in the provision of healthcare services across the continent. ... United European Gastroenterology (UEG), have been announced today and ... of the burden of GI disorders across ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... folks, this is my last article of the year, and I ... so my New Year's resolution for this column is bring back ... problem is that I simply have not gone to as many ... I will need to remedy!) , ,Looking over 2006, my focus ...
... on Google , Yahoo , or MSN ... Today, even the experts aren't sure exactly what it's going ... pay-per click (PPC) infrastructures to increase the relevancy and quality ... link farms and other sites without original or meaningful content. ...
... Wis. - The nation's space agency announced this month it ... enough to pack for the longer trip to Mars . ... bypass the Earth's lifeless satellite and head directly for ... others say the government should get out of the business of ...
Cached Biology Technology:2006: A great biotech financing year, unless you were going public! 22006: A great biotech financing year, unless you were going public! 32006: A great biotech financing year, unless you were going public! 42006: A great biotech financing year, unless you were going public! 5It takes more than money to reach the top 2It takes more than money to reach the top 3It takes more than money to reach the top 4Flying to the moon? Take Wisconsin tech along 2Flying to the moon? Take Wisconsin tech along 3Flying to the moon? Take Wisconsin tech along 4
(Date:10/17/2014)... in German . ... day in order to reproduce? And why are there two ... the latest issue of the research journal Molecular Human ... Steven Ramm from Bielefeld University Bielefeld has compiled this special ... for a female to copulate with several males in quick ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... that restoring a gene often silenced in lung cancer causes ... new strategy for treating the disease. , The research ... or silenced in a large majority of lung cancers, and ... pancreas. The work was led by scientists at The Ohio ...
... Researchers at the Salk Institute for Biological Studies discovered ... strands of DNA to protect the integrity of chromosomes. ... question that has long puzzled scientists. , The natural ... DNA that a cell's repair machinery is designed to ...
... have discovered the presence of functional ion channels in ... like electrical wires and permit ESCs, versatile cells that ... of the body, to conduct and pass along electric ... these channels in implanted cells, derived from stem cells, ...
Cached Biology News:Restoring silenced suppressor gene kills lung-cancer cells 2Normal chromosome ends elicit a limited DNA damage response 2Stem cells' electric abilities might help their safe clinical use 2
...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
... Mitochondria Derived Activator of Caspase/DIABLO Liquid. ... 7.5 AVOID FREEZE/THAW CYCLES. Amino acid residues 56 ... terminal His•Tag ® sequence was expressed in ... is released along with cytochrome c ...
... Decorin ( Abpromise for all ... Synthetic peptide: IGPEVPDDRDFEPS conjugated to ... of Human Decorin (fragment 36-49 of ... Entrez GeneID: ...
Biology Products: